Vir Biotechnology VIR Cash Flow Statement (2018-2026)

NASDAQ VIR
$11.52 +0.07 (+0.61%)
As of: Sep 4, 2026 · 2:22 PM EDT
Reported Financials

Vir Biotechnology Quarterly Cash Flow Statement

Periods 32 quarters
Latest Jun 2026

Vir Biotechnology reported cash from operations of $123.33M and free cash flow of $123.29M for the quarter ended Jun 2026, up 202.6% year over year. This cash flow statement covers 32 quarters of results from Sep 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
110.43M525.25M518.62M-76.49M175.31M-101.60M-140.96M-194.78M-163.41M-115.97M-65.28M-138.38M-213.72M-104.59M-120.97M-110.96M-163.14M-42.92M-125.69M80.08M
Share-based Compensation
22.94M24.37M25.30M27.10M24.81M24.86M25.48M30.62M26.94M28.27M23.76M22.16M16.70M15.84M14.06M12.45M11.36M11.21M12.09M12.39M
Deferred Taxes
-1.06M0.06M-2.64M
Gains from Equity Investments
-164.07M26.02M95.04M11.39M13.59M-8.88M13.10M5.09M2.71M0.99M5.92M-0.43M-1.13M1.17M-6.38M3.38M-1.33M2.61M0.17M1.72M
Gains from Investment Securities
Asset Writedowns and Impairment
2.76M11.04M
Cash from Operations
-105.81M7.70M550.09M960.14M117.90M35.13M-125.78M-389.25M-155.83M-107.93M-109.39M-77.85M-171.48M-87.64M-78.12M-120.22M-167.57M-25.88M-132.39M123.33M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.62M-0.61M-1.07M-0.66M3.05M7.63M9.37M3.00M-2.31M-1.35M-0.24M-2.64M-0.35M-2.17M-4.09M-2.52M-1.31M-1.55M-0.39M-0.32M
Depreciation & Amortization (CF)Depreciation & Amortization
1.40M1.40M1.42M1.50M1.60M2.35M5.64M4.60M4.50M4.48M4.52M4.26M2.90M2.89M2.87M2.92M3.00M2.90M2.81M2.80M
Change in Working Capital
Change in Receivables
93.00M680.08M450.08M-883.77M-58.18M-278.17M-2.09M-0.95M3.61M0.40M-2.69M0.05M8.75M
Change in Account Payables
-5.89M0.79M3.83M-1.39M-4.45M2.80M6.56M-0.93M-7.53M2.63M0.73M-2.89M3.11M-1.94M-1.42M8.86M-5.40M2.96M-4.23M12.31M
Change in Accured Expenses
8.80M71.99M433.56M-288.18M-80.24M-80.66M-4.04M-265.73M-47.15M-41.92M-30.00M-4.79M19.27M-48.49M18.01M-26.01M-11.62M10.10M-17.22M8.39M
Other Working Capital Changes
-0.89M2.48M17.58M-2.02M-40.06M63.86M-9.49M-17.80M-26.90M17.91M-50.16M0.48M-1.50M28.16M-5.06M-0.88M-4.21M2.78M-2.27M-3.79M
Investing Activities
Capital Expenditures
6.01M13.07M15.84M20.60M18.99M12.57M6.87M9.46M3.71M1.53M1.87M0.67M2.77M2.00M1.63M2.54M0.32M0.35M0.39M0.03M
Sales of Property, Plant and Equipment
0.01M-0.00M0.01M-0.02M0.53M0.38M0.01M2.46M0.28M0.04M0.04M-0.11M
Change in Acquisitions & Divestments
79.86M84.84M266.67M489.46M549.55M447.67M715.71M592.70M483.29M361.51M301.14M301.86M251.32M305.17M342.93M170.60M154.99M
Cash from Investing Activities
73.86M-377.58M-105.39M-272.33M-662.61M-153.13M98.08M230.31M-58.95M-104.81M28.42M211.61M118.60M140.74M126.82M56.46M40.45M86.65M11.84M-197.14M
Financing Activities
Other financing activities
3.69M3.44M0.48M1.58M1.54M0.93M2.31M0.74M0.34M0.89M0.22M2.38M1.16M0.60M1.16M1.04M0.17M1.44M
Change in Capital Stock
Net Shares Issued and Repurchased
3.29M1.50M2.05M
Net Equity Issued and Repurchased
-85.21M162.35M-0.14M
Misc.
Cash from Financing Activities
3.63M5.67M27.68M3.08M1.99M2.01M2.34M3.18M0.28M1.68M0.15M2.94M0.03M1.26M0.60M2.05M0.10M1.04M162.52M78.38M
Change in Cash
-28.32M-364.22M472.38M690.89M-542.72M-116.00M-25.36M-155.75M-214.51M-211.06M-80.82M136.70M-52.85M54.37M49.30M-61.72M-127.02M61.81M41.97M4.56M
Free Cash Flow
-111.82M-5.37M534.25M939.54M98.91M22.55M-132.65M-398.70M-159.54M-109.46M-111.26M-78.51M-174.25M-89.63M-79.75M-122.76M-167.89M-26.22M-132.78M123.29M
Net Cash Flow
-28.32M-364.22M472.38M690.89M-542.72M-116.00M-25.36M-155.75M-214.51M-211.06M-80.82M136.70M-52.85M54.37M49.30M-61.72M-127.02M61.81M41.97M4.56M